Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Capricor Therapeutics in a research report on Friday, January 5th. They set an “overweight” rating and a $8.00 price objective for the company. StockNews.com raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $5.04 on Thursday. The firm has a 50 day simple moving average of $5.56 and a 200-day simple moving average of $4.34. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $8.22. The stock has a market cap of $158.76 million, a price-to-earnings ratio of -5.79 and a beta of 3.99.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.21. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. The business had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $5.80 million. Equities analysts expect that Capricor Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Jump Financial LLC acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 52,800 shares of the biotechnology company’s stock, valued at approximately $258,000. Jump Financial LLC owned approximately 0.17% of Capricor Therapeutics at the end of the most recent quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.